Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Vaxxinity, Inc. - Class A Common Stock (NQ: VAXX ) N/A UNCHANGED Last Price Updated: 4:00 PM EDT, May 8, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Vaxxinity, Inc. - Class A Common Stock < Previous 1 2 Next > Vaxxinity Issues Shareholder Letter April 19, 2024 From Vaxxinity, Inc. Via GlobeNewswire Vaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common Stock April 19, 2024 From Vaxxinity, Inc. Via GlobeNewswire Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meeting March 28, 2024 Presentation will address the Company’s clinical data in Parkinson’s disease From Vaxxinity, Inc. Via GlobeNewswire Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates March 27, 2024 From Vaxxinity, Inc. Via GlobeNewswire Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson’s Disease at AD/PD™ 2024 March 07, 2024 UB-312 is first immunotherapy to show reduction of pathological alpha-synuclein in cerebrospinal fluid of Parkinson’s patients From Vaxxinity, Inc. Via GlobeNewswire Vaxxinity’s Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published February 15, 2024 From Vaxxinity, Inc. Via GlobeNewswire Vaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024 February 13, 2024 From Vaxxinity, Inc. Via GlobeNewswire Vaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases with University of Florida January 30, 2024 From Vaxxinity, Inc. Via GlobeNewswire Vaxxinity Announces Collaboration on Space Medicine Research with University of Central Florida January 18, 2024 From Vaxxinity, Inc. Via GlobeNewswire Vaxxinity to Present at the 2024 J.P. Morgan Healthcare Conference January 03, 2024 From Vaxxinity, Inc. Via GlobeNewswire Vaxxinity to Present at Upcoming November Medical and Investor Conferences November 13, 2023 From Vaxxinity, Inc. Via GlobeNewswire Vaxxinity Reports Third Quarter 2023 Financial Results and Provides Corporate Update November 08, 2023 From Vaxxinity, Inc. Via GlobeNewswire Vaxxinity to Present at Upcoming Investor Conferences in September August 29, 2023 From Vaxxinity, Inc. Via GlobeNewswire Vaxxinity Announces Publication of UB-311 Safety, Tolerability, Immunogenicity, and Clinical Efficacy Data from Phase 2a Trial in Alzheimer’s Disease August 10, 2023 From Vaxxinity, Inc. Via GlobeNewswire Vaxxinity Reports Second Quarter 2023 Financial Results and Provides Corporate Update August 09, 2023 From Vaxxinity, Inc. Via GlobeNewswire Vaxxinity Appoints Peter Powchik, M.D., to Executive Vice President, Global Scientific Director July 27, 2023 From Vaxxinity, Inc. Via GlobeNewswire Vaxxinity Demonstrates Target Engagement of Toxic Alpha-Synuclein in Parkinson’s Patients July 17, 2023 From Vaxxinity, Inc. Via GlobeNewswire Vaxxinity Announces UB-312 Successfully Met Primary Objectives of Phase 1 Clinical Trial in Parkinson’s Disease June 22, 2023 From Vaxxinity, Inc. Via GlobeNewswire Vaxxinity Reports First Quarter 2023 Financial Results and Provides Corporate Update May 09, 2023 From Vaxxinity, Inc. Via GlobeNewswire Vaxxinity to Present at World Vaccine Congress, American Academy of Neurology, and BNA2023 Festival of Neuroscience in April March 28, 2023 From Vaxxinity, Inc. Via GlobeNewswire Vaxxinity Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Updates March 27, 2023 From Vaxxinity, Inc. Via GlobeNewswire Vaxxinity Joins TransCelerate Research and Development Consortium March 21, 2023 From Vaxxinity, Inc. Via GlobeNewswire Vaxxinity Announces First Subjects Dosed in Phase 1 Clinical Trial of VXX-401, Investigational Anti-PCSK9 Vaccine to Treat Hypercholesterolemia March 20, 2023 From Vaxxinity, Inc. Via GlobeNewswire Vaxxinity to Present at Upcoming March Scientific and Medical Conferences March 02, 2023 Vaxxinity to present new preclinical data on anti-tau Alzheimer’s vaccine candidate VXX-301 at AD/PD International Conference From Vaxxinity, Inc. Via GlobeNewswire Vaxxinity Announces Board Appointments and Establishes New Headquarters in Florida February 01, 2023 From Vaxxinity, Inc. Via GlobeNewswire Vaxxinity to Present at the 2023 J.P. Morgan Healthcare Conference January 05, 2023 From Vaxxinity, Inc. Via GlobeNewswire Vaxxinity Announces Positive Topline Pivotal Phase 3 COVID-19 Booster Data for UB-612 December 02, 2022 From Vaxxinity, Inc. Via GlobeNewswire Vaxxinity Reports Third Quarter 2022 Financial Results and Provides Corporate Update November 10, 2022 From Vaxxinity, Inc. Via GlobeNewswire Vaxxinity to Host First Analyst and R&D Day in New York City on November 10, 2022 November 03, 2022 From Vaxxinity, Inc. Via GlobeNewswire Vaxxinity to Present at Upcoming Investor Conferences in November November 01, 2022 From Vaxxinity, Inc. Via GlobeNewswire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
